Beam Therapeutics Inc. (BEAM)
NASDAQ: BEAM · Real-Time Price · USD
22.83
-1.20 (-4.99%)
At close: Nov 13, 2026, 4:00 PM EST
23.17
+0.34 (1.49%)
After-hours: Nov 13, 2026, 7:52 PM EST
Beam Therapeutics Employees
Beam Therapeutics had 557 employees as of September 30, 2026. The number of employees increased by 47 or 9.22% compared to the same quarter last year. That makes Beam Therapeutics the 19,289th largest employer in the world and 2,602nd in the United States.
Employees
557
Change (1Y)
47
Growth (1Y)
9.22%
Revenue / Employee
$263,275
Profits / Employee
-$194,531
Market Cap
2.28B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2026 | 557 | 47 | 9.22% |
| Jun 30, 2026 | 540 | 31 | 6.09% |
| Mar 31, 2026 | 522 | 129 | 32.82% |
| Dec 31, 2025 | 511 | 28 | 5.80% |
| Sep 30, 2025 | 510 | 38 | 8.05% |
| Jun 30, 2025 | 509 | 48 | 10.41% |
| Mar 31, 2025 | 393 | 47 | 13.58% |
| Dec 31, 2024 | 483 | 47 | 10.78% |
| Sep 30, 2024 | 472 | 33 | 7.52% |
| Jun 30, 2024 | 461 | -71 | -13.35% |
| Mar 31, 2024 | 346 | -177 | -33.84% |
| Dec 31, 2023 | 436 | -71 | -14.00% |
| Sep 30, 2023 | 439 | -68 | -13.41% |
| Jun 30, 2023 | 532 | 56 | 11.76% |
| Mar 31, 2023 | 523 | 129 | 32.74% |
| Dec 31, 2022 | 507 | 166 | 48.68% |
| Sep 30, 2022 | 507 | 201 | 65.69% |
| Jun 30, 2022 | 476 | 210 | 78.95% |
| Mar 31, 2022 | 394 | 178 | 82.41% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| ADMA Biologics | 647 |
| Arcus Biosciences | 601 |
| Vir Biotechnology | 367 |
| Biohaven | 274 |
| Immunome | 267 |
| Celldex Therapeutics | 198 |
| Pharvaris | 148 |
| Septerna | 134 |
BEAM News
- 3 days ago - Beam Therapeutics price target raised to $33 from $30 at Wedbush - TheFly
- 3 days ago - Beam Therapeutics reports BEACON trial achieves primary efficacy endpoint - TheFly
- 3 days ago - Beam Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference - Transcripts
- 4 days ago - Beam Therapeutics Announces Positive Topline Pivotal Data from BEACON Phase 1/2 Trial of Risto-cel in Patients with Sickle Cell Disease - GlobeNewsWire
- 8 days ago - Beam Therapeutics price target lowered to $51 from $55 at Guggenheim - TheFly
- 9 days ago - Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire
- 9 days ago - Beam Therapeutics price target lowered to $41 from $43 at BofA - TheFly
- 9 days ago - Beam Therapeutics price target raised to $30 from $28 at Wedbush - TheFly